A scientist who decided ideas were cheap
Vivek Lal likes to say that ideas are a dime a dozen. Coming from a man with more than a hundred peer-reviewed papers and a wall of patents, that is either false modesty or hard-won wisdom. It is the second one. He has watched too many founders fall in love with a clever notion before checking whether anyone actually wanted it.
So here is what he built instead. resbiotic is a Birmingham-based wellness company that makes probiotic and prebiotic supplements - the part that sets it apart is that the formulas are run through actual clinical testing before they reach a shelf. Lal founded it in 2022 after doing the math that bothered him: roughly 60% of American adults take supplements, and the vast majority of those products carry no real scientific validation. He had spent his career generating exactly that kind of validation in a university lab. The gap was the business.
He is the Founder and CEO. He is also, simultaneously, the Director of Clinical Innovation at the University of Alabama at Birmingham's Marnix Heersink Institute of Biomedical Innovation, a professor, and the head of UAB's Pulmonary Microbiome Lab. The lab work funded by the NIH and the American Heart Association is not a former life he left behind. It is the supply chain for everything else.
The islands, then everywhere else
Lal grew up in the Andaman Islands, a remote archipelago in the Bay of Bengal, in a household where achievement was the family language. He went into medicine partly to honor his mother's hopes, then kept going further than the script called for. Medical school, residency, a clinical fellowship in neonatal and perinatal medicine, and a research fellowship in pulmonary and vascular biology - all at UT Southwestern Medical Center in Dallas. Then an executive program in drug and device development at MIT, because apparently the medical training was not enough scaffolding for what he had in mind.
The throughline is a piece of advice from his father that he still quotes: if you ever wonder how to do something, just start, and you will end up looking back wondering how you did it. It is the kind of line that sounds like a fridge magnet until you notice the man took it literally and built three companies.
Three companies, one operating system
The first venture was the most personal. Lal and his wife - also a physician-entrepreneur - co-founded Urgent Care for Children, a pediatric urgent care chain across the Southeast. That was his apprenticeship in the unglamorous mechanics of running a business: payroll, real estate, the difference between a good idea and a going concern. The couple has twin children, which means they were learning pediatric urgent care on two fronts at once.
Next came Alveolus Bio in 2021, a platform biotech spun out of his UAB research to pursue FDA-track pulmonary drug development. Then resbiotic in 2022, the consumer-facing arm. The three businesses are not a scattershot portfolio. They are the same scientific engine pointed at three different timelines - the multi-year drug pipeline at Alveolus, the faster consumer products at resbiotic, the cash-generating clinics at Urgent Care.
The "Gut-X Axis" bet
resbiotic's organizing scientific idea is what the company calls the Gut-X Axis - the premise that the bacteria living in your digestive system send signals that ripple out to the rest of the body. The company's flagship product extended that thinking to respiratory wellness, and resbiotic has since pushed the platform toward metabolic, women's, and bone categories. Whatever you make of the science, the marketing instinct is sharp. As Lal puts it, deadpan: anyone who breathes is a customer, which actually is true.
He insists every resbiotic employee personally take the products. It is part conviction, part quality control, and part a tell about how he thinks. He does not want the company selling anything the team would not swallow themselves. "We want all of our employees to try each of our products," he has said - a low bar that an alarming number of supplement companies cannot clear.
Radical candor and a swimmer
Inside the company, Lal runs on what he calls radical candor - he expects teammates to challenge each other with ideas, data, and facts rather than defer to the founder. It tracks with a man who spent years in peer review, where being wrong in public is the job. For all that, he describes himself with a shrug: "I don't consider myself very important." He admires Elon Musk for bulldozing entrenched industries, and he has said he would love to talk respiratory science with the swimmer Michael Phelps - a wish that makes more sense the longer you think about lung capacity.
In September 2025, resbiotic closed an $8 million Series A, backed by Sororibus Capital and Biostack Ventures, bringing the company's total funding to $14.5 million. The plan for the money is unglamorous and exactly on brand: more products, wider retail and ecommerce distribution, and a stronger business-to-business ingredients arm. No fireworks. Just a scientist, still convinced that the proof should come before the pitch, scaling the proof.